Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Journey Medical Corporation (NASDAQ: DERM)
DERM Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
62%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
4.50%
DERM Stock Analysis
DERM
PE Ratio:
DERM
PEG Ratio:
DERM
Forward EPS Growth (12 month):
400.00%
DERM
PS Ratio:
2.6
DERM
PSG Ratio:
DERM
Forward Revenue Growth (12 month):
66.70%
DERM Articles
No data was found